In This Article:
As global markets continue to show resilience, the Swedish market has been no exception, with strong performances in various sectors. In this context, growth companies with high insider ownership are particularly appealing due to their potential for robust performance and alignment of interests between management and shareholders.
Top 10 Growth Companies With High Insider Ownership In Sweden
| Name | Insider Ownership | Earnings Growth |
| CTT Systems (OM:CTT) | 16.9% | 24.8% |
| Truecaller (OM:TRUE B) | 29.5% | 21.6% |
| Fortnox (OM:FNOX) | 21.1% | 22.6% |
| Biovica International (OM:BIOVIC B) | 18.8% | 73.8% |
| Magle Chemoswed Holding (OM:MAGLE) | 14.9% | 72.2% |
| Yubico (OM:YUBICO) | 37.5% | 43.7% |
| BioArctic (OM:BIOA B) | 34% | 102.8% |
| KebNi (OM:KEBNI B) | 37.8% | 86.1% |
| Calliditas Therapeutics (OM:CALTX) | 12.7% | 51.9% |
| InCoax Networks (OM:INCOAX) | 18.1% | 115.5% |
We're going to check out a few of the best picks from our screener tool.
BioArctic
Simply Wall St Growth Rating: ★★★★★★
Overview: BioArctic AB (publ) develops biological drugs for central nervous system disorders in Sweden and has a market cap of SEK14.05 billion.
Operations: BioArctic AB generates SEK252.21 million in revenue from its biotechnology segment.
Insider Ownership: 34%
Earnings Growth Forecast: 102.8% p.a.
BioArctic, a growth company with high insider ownership, is forecasted to achieve significant revenue growth of 39.6% annually and become profitable within three years. Despite recent volatility in its share price, it trades at 76.7% below estimated fair value and analysts expect a substantial price increase. Recent approvals of Leqembi for Alzheimer's treatment in multiple countries bolster BioArctic's prospects, supported by strong clinical trial results and strategic partnerships with Eisai.
EQT
Simply Wall St Growth Rating: ★★★★★☆
Overview: EQT AB (publ) is a global private equity firm specializing in private capital and real asset segments, with a market cap of approximately SEK405.21 billion.
Operations: The company's revenue segments include Central (€37.20 million), Real Assets (€878.70 million), and Private Capital (€1.28 billion).
Insider Ownership: 30.9%
Earnings Growth Forecast: 56.8% p.a.
EQT, with substantial insider ownership, is poised for significant earnings growth at 56.8% annually, outpacing the Swedish market's 16%. Recent M&A activities highlight its strategic expansion ambitions, including potential bids for Compass Education and Karo Healthcare. Despite some large one-off items impacting results, EQT reported a notable rise in net income to €282 million for H1 2024 from €120 million the previous year. The company also initiated a share repurchase program to optimize capital structure.